Do HIV care providers appropriately manage hepatitis B in coinfected patients treated with antiretroviral therapy?

Mamta K. Jain, Christopher K. Opio, Chukwuma C. Osuagwu, Rathi Pillai, Philip Keiser, William M. Lee

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background. The common occurrence of hepatitis B virus (HBV) infection in patients who carry the human immunodeficiency virus (HIV) demands that both viruses be recognized, evaluated, and treated when appropriate. Methods. We identified 357 HIV- and hepatitis B surface antigen-positive patients who underwent testing from 1999 to 2003; 155 patients who were new to our clinic and who initiated therapy for HIV and HBV coinfection were considered for inclusion in the study. The frequency of HIV testing (to determine HIV load and CD4 + cell count) performed during the first year of therapy was compared with the frequency of HBV measurements (to determine hepatitis B e antigen, antibody to hepatitis B e antigen, and HBV load), abdominal ultrasound examination, and measurement of levels of α-fetoprotein in serum. Results. HBV load data were obtained for only 16% of patients before initiation of antiretroviral therapy (ART), whereas HIV load was determined for 99% of patients before initiation of ART. The total number of HIV load measurements obtained during the first year after ART initiation was 497 (median number of HIV load measurements per patient, 3.0), compared with 85 measurements of HBV load (median number of HBV load measurements per patient, <1; P < .001). The percentage of patients who received any level of HBV monitoring (i.e., tests to determine hepatitis B e antigen, antibody to hepatitis B e antigen, and HBV load) after ART initiation increased from 7% in 1999 to 52% in 2001 (P < .001), whereas the percentage of patients who underwent HIV load testing remained at 80%-90% during the same period. Conclusions. Health care providers treating patients with HIV infection during the period 1999-2003 infrequently monitored HBV response in coinfected patients, but they systematically monitored HIV response after ART initiation. Improved physician adherence to guidelines that better delineate HBV treatment and monitoring for patients with HIV-HBV coinfection is needed.

Original languageEnglish (US)
Pages (from-to)996-1000
Number of pages5
JournalClinical Infectious Diseases
Volume44
Issue number7
DOIs
StatePublished - Apr 1 2007
Externally publishedYes

Fingerprint

Hepatitis B
Hepatitis B virus
HIV
Hepatitis B e Antigens
Therapeutics
Virus Diseases
Coinfection
Fetal Proteins
Guideline Adherence
Antibodies
Physiologic Monitoring
CD4 Lymphocyte Count
Hepatitis B Surface Antigens
Health Personnel
Viruses
Physicians

ASJC Scopus subject areas

  • Immunology

Cite this

Do HIV care providers appropriately manage hepatitis B in coinfected patients treated with antiretroviral therapy? / Jain, Mamta K.; Opio, Christopher K.; Osuagwu, Chukwuma C.; Pillai, Rathi; Keiser, Philip; Lee, William M.

In: Clinical Infectious Diseases, Vol. 44, No. 7, 01.04.2007, p. 996-1000.

Research output: Contribution to journalArticle

Jain, Mamta K. ; Opio, Christopher K. ; Osuagwu, Chukwuma C. ; Pillai, Rathi ; Keiser, Philip ; Lee, William M. / Do HIV care providers appropriately manage hepatitis B in coinfected patients treated with antiretroviral therapy?. In: Clinical Infectious Diseases. 2007 ; Vol. 44, No. 7. pp. 996-1000.
@article{52b2e12e03d84517bcdb2def7297e40d,
title = "Do HIV care providers appropriately manage hepatitis B in coinfected patients treated with antiretroviral therapy?",
abstract = "Background. The common occurrence of hepatitis B virus (HBV) infection in patients who carry the human immunodeficiency virus (HIV) demands that both viruses be recognized, evaluated, and treated when appropriate. Methods. We identified 357 HIV- and hepatitis B surface antigen-positive patients who underwent testing from 1999 to 2003; 155 patients who were new to our clinic and who initiated therapy for HIV and HBV coinfection were considered for inclusion in the study. The frequency of HIV testing (to determine HIV load and CD4 + cell count) performed during the first year of therapy was compared with the frequency of HBV measurements (to determine hepatitis B e antigen, antibody to hepatitis B e antigen, and HBV load), abdominal ultrasound examination, and measurement of levels of α-fetoprotein in serum. Results. HBV load data were obtained for only 16{\%} of patients before initiation of antiretroviral therapy (ART), whereas HIV load was determined for 99{\%} of patients before initiation of ART. The total number of HIV load measurements obtained during the first year after ART initiation was 497 (median number of HIV load measurements per patient, 3.0), compared with 85 measurements of HBV load (median number of HBV load measurements per patient, <1; P < .001). The percentage of patients who received any level of HBV monitoring (i.e., tests to determine hepatitis B e antigen, antibody to hepatitis B e antigen, and HBV load) after ART initiation increased from 7{\%} in 1999 to 52{\%} in 2001 (P < .001), whereas the percentage of patients who underwent HIV load testing remained at 80{\%}-90{\%} during the same period. Conclusions. Health care providers treating patients with HIV infection during the period 1999-2003 infrequently monitored HBV response in coinfected patients, but they systematically monitored HIV response after ART initiation. Improved physician adherence to guidelines that better delineate HBV treatment and monitoring for patients with HIV-HBV coinfection is needed.",
author = "Jain, {Mamta K.} and Opio, {Christopher K.} and Osuagwu, {Chukwuma C.} and Rathi Pillai and Philip Keiser and Lee, {William M.}",
year = "2007",
month = "4",
day = "1",
doi = "10.1086/512367",
language = "English (US)",
volume = "44",
pages = "996--1000",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Do HIV care providers appropriately manage hepatitis B in coinfected patients treated with antiretroviral therapy?

AU - Jain, Mamta K.

AU - Opio, Christopher K.

AU - Osuagwu, Chukwuma C.

AU - Pillai, Rathi

AU - Keiser, Philip

AU - Lee, William M.

PY - 2007/4/1

Y1 - 2007/4/1

N2 - Background. The common occurrence of hepatitis B virus (HBV) infection in patients who carry the human immunodeficiency virus (HIV) demands that both viruses be recognized, evaluated, and treated when appropriate. Methods. We identified 357 HIV- and hepatitis B surface antigen-positive patients who underwent testing from 1999 to 2003; 155 patients who were new to our clinic and who initiated therapy for HIV and HBV coinfection were considered for inclusion in the study. The frequency of HIV testing (to determine HIV load and CD4 + cell count) performed during the first year of therapy was compared with the frequency of HBV measurements (to determine hepatitis B e antigen, antibody to hepatitis B e antigen, and HBV load), abdominal ultrasound examination, and measurement of levels of α-fetoprotein in serum. Results. HBV load data were obtained for only 16% of patients before initiation of antiretroviral therapy (ART), whereas HIV load was determined for 99% of patients before initiation of ART. The total number of HIV load measurements obtained during the first year after ART initiation was 497 (median number of HIV load measurements per patient, 3.0), compared with 85 measurements of HBV load (median number of HBV load measurements per patient, <1; P < .001). The percentage of patients who received any level of HBV monitoring (i.e., tests to determine hepatitis B e antigen, antibody to hepatitis B e antigen, and HBV load) after ART initiation increased from 7% in 1999 to 52% in 2001 (P < .001), whereas the percentage of patients who underwent HIV load testing remained at 80%-90% during the same period. Conclusions. Health care providers treating patients with HIV infection during the period 1999-2003 infrequently monitored HBV response in coinfected patients, but they systematically monitored HIV response after ART initiation. Improved physician adherence to guidelines that better delineate HBV treatment and monitoring for patients with HIV-HBV coinfection is needed.

AB - Background. The common occurrence of hepatitis B virus (HBV) infection in patients who carry the human immunodeficiency virus (HIV) demands that both viruses be recognized, evaluated, and treated when appropriate. Methods. We identified 357 HIV- and hepatitis B surface antigen-positive patients who underwent testing from 1999 to 2003; 155 patients who were new to our clinic and who initiated therapy for HIV and HBV coinfection were considered for inclusion in the study. The frequency of HIV testing (to determine HIV load and CD4 + cell count) performed during the first year of therapy was compared with the frequency of HBV measurements (to determine hepatitis B e antigen, antibody to hepatitis B e antigen, and HBV load), abdominal ultrasound examination, and measurement of levels of α-fetoprotein in serum. Results. HBV load data were obtained for only 16% of patients before initiation of antiretroviral therapy (ART), whereas HIV load was determined for 99% of patients before initiation of ART. The total number of HIV load measurements obtained during the first year after ART initiation was 497 (median number of HIV load measurements per patient, 3.0), compared with 85 measurements of HBV load (median number of HBV load measurements per patient, <1; P < .001). The percentage of patients who received any level of HBV monitoring (i.e., tests to determine hepatitis B e antigen, antibody to hepatitis B e antigen, and HBV load) after ART initiation increased from 7% in 1999 to 52% in 2001 (P < .001), whereas the percentage of patients who underwent HIV load testing remained at 80%-90% during the same period. Conclusions. Health care providers treating patients with HIV infection during the period 1999-2003 infrequently monitored HBV response in coinfected patients, but they systematically monitored HIV response after ART initiation. Improved physician adherence to guidelines that better delineate HBV treatment and monitoring for patients with HIV-HBV coinfection is needed.

UR - http://www.scopus.com/inward/record.url?scp=33947415368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947415368&partnerID=8YFLogxK

U2 - 10.1086/512367

DO - 10.1086/512367

M3 - Article

VL - 44

SP - 996

EP - 1000

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 7

ER -